研究者業績

Shimmura Shigeto

  (榛村 重人)

Profile Information

Affiliation
Professor, Clinical Regenerative Medicine, Fujita Health University

Researcher number
00235780
J-GLOBAL ID
200901071718947262
researchmap Member ID
1000308202

External link

Education

 1

Papers

 281
  • Shinri Sato, Yoko Ogawa, Eisuke Shimizu, Kazuki Asai, Takahiro Okazaki, Robert Rusch, Masatoshi Hirayama, Shigeto Shimmura, Kazuno Negishi, Kazuo Tsubota
    The ocular surface, 32 198-210, Apr, 2024  
    PURPOSE: Aging is a well-established risk factor for meibomian gland dysfunction (MGD). We previously reported an accelerated cellular senescence phenomenon in the lacrimal glands of a murine model of chronic graft-versus-host disease (cGVHD). Herein, we aimed to elucidate the relationship between cellular senescence and MGD in cGVHD mice, utilizing the senolytic agent ABT-263. METHODS: A cGVHD mouse model was established through allogeneic bone marrow transplantation (BMT) from B10.D2 to BALB/c mice. Subsequently, cGVHD mice were treated with either ABT-263 or vehicle. The eyelids of recipients were analyzed at 4-week intervals post-BMT in both groups. RESULTS: Meibomian gland (MG) area was significantly smaller in cGVHD mice than in syngeneic control mice. ABT-263-treated mice retained a significantly larger MG area than their vehicle-treated counterparts. Pathological and immunohistochemical examinations revealed significant reductions in eyelid tissue inflammation and pathological fibrosis in the ABT-263 group compared to that in the vehicle-treated group. Additionally, expression of DNA damage markers, senescent cell markers, and senescence-associated secretory phenotype (SASP) factors was elevated in the eyelids of cGVHD mice compared with that in syngeneic mice. The expression of these cellular senescence-associated molecules was considerably suppressed in ABT-263-treated eyelids compared to that in vehicle-treated ones. CONCLUSIONS: Cellular senescence, along with expression of SASP factors, exhibited increased activity in the eyelids, particularly in the MGs of cGVHD mice. ABT-263 mitigated the severity of MGD. These findings highlight the potential of targeting cellular senescence as an effective approach for MGD treatment in cGVHD.
  • Shigeto Shimmura, Emi Inagaki, Masatoshi Hirayama, Shin Hatou
    The Keio journal of medicine, 73(1) 1-7, Mar 25, 2024  
    Regenerative medicine is a highly anticipated field with hopes to provide cures for previously uncurable diseases such as spinal cord injuries and retinal blindness. Most regenerative medical products use either autologous or allogeneic stem cells, which may or may not be genetically modified. The introduction of induced-pluripotent stem cells (iPSCs) has fueled research in the field, and several iPSC-derived cells/tissues are currently undergoing clinical trials. The cornea is one of the pioneering areas of regenerative medicine, and already four cell therapy products are approved for clinical use in Japan. There is one other government-approved cell therapy product approved in Europe, but none are approved in the USA at present. The cornea is transparent and avascular, making it unique as a target for stem cell therapy. This review discusses the unique properties of the cornea and ongoing research in the field.
  • Anna Altshuler, Aya Amitai-Lange, Waseem Nasser, Shalini Dimri, Swarnabh Bhattacharya, Beatrice Tiosano, Ramez Barbara, Daniel Aberdam, Shigeto Shimmura, Ruby Shalom-Feuerstein
    Stem cell reports, 18(12) 2313-2327, Dec 12, 2023  
    Recently, the murine cornea has reemerged as a robust stem cell (SC) model, allowing individual SC tracing in living animals. The cornea has pioneered seminal discoveries in SC biology and regenerative medicine, from the first corneal transplantation in 1905 to the identification of limbal SCs and their transplantation to successfully restore vision in the early 1990s. Recent experiments have exposed unexpected properties attributed to SCs and progenitors and revealed flexibility in the differentiation program and a key role for the SC niche. Here, we discuss the limbal SC model and its broader relevance to other tissues, disease, and therapy.
  • Saki Sakakura, Emi Inagaki, Tomoko Sayano, Risa Yamazaki, Noemi Fusaki, Shin Hatou, Masatoshi Hirayama, Kazuo Tsubota, Kazuno Negishi, Hideyuki Okano, Shigeto Shimmura
    Regenerative therapy, 24 592-601, Dec, 2023  
    INTRODUCTION: Fuchs endothelial corneal dystrophy (FECD) is the leading cause of corneal blindness in developed countries. Corneal endothelial cells in FECD are susceptive to oxidative stress, leading to mitochondrial dysfunction and cell death. Oxidative stress causes many forms of cell death including parthanatos, which is characterized by translocation of apoptosis-inducing factor (AIF) to the nucleus with upregulation of poly (ADP-ribose) polymerase 1 (PARP-1) and poly (ADP-ribose) (PAR). Although cell death is an important aspect of FECD, previous reports have often analyzed immortalized cell lines, making the evaluation of cell death difficult. Therefore, we established a new in vitro FECD model to evaluate the pathophysiology of FECD. METHODS: Corneal endothelial cells were derived from disease-specific induced pluripotent stem cells (iPSCs). Hydrogen peroxide (H2O2) was used as a source for oxidative stress to mimic the pathophysiology of FECD. We investigated the responses to oxidative stress and the involvement of parthanatos in FECD-corneal endothelial cells. RESULTS: Cell death ratio and oxidative stress level were upregulated in FECD with H2O2 treatment compared with non-FECD control, indicating the vulnerability of oxidative stress in FECD. We also found that intracellular PAR, as well as PARP-1 and AIF in the nucleus were upregulated in FECD. Furthermore, PARP inhibition, but not pan-caspase inhibition, rescued cell death, DNA double-strand breaks, mitochondrial membrane potential depolarization and energy depletion, suggesting that cell death was mainly due to parthanatos. CONCLUSIONS: We report that parthanatos may be involved in the pathophysiology of FECD and targeting this cell death pathway may be a potential therapeutic approach for FECD.
  • Saki Sakakura, Emi Inagaki, Yuichiro Ochiai, Masatoshi Yamamoto, Naofumi Takai, Taeko Nagata, Kazunari Higa, Yasunori Sato, Hiroshi Toshida, Dogru Murat, Masatoshi Hirayama, Yoko Ogawa, Kazuno Negishi, Shigeto Shimmura
    International journal of molecular sciences, 24(22), Nov 20, 2023  
    Tear film instability is a major cause of dry eye disease. In order to treat patients with short tear film breakup time (TBUT)-type dry eye, the development of tear film stabilizing agents is essential. However, the lack of an appropriate animal model of tear film instability has made drug development difficult. Although rabbit dry eye models have been reported in the past, there are only a few reports that focus on tear film instability. Herein, we assessed the tear film stability of a rabbit dry eye model induced by dacryoadenectomy. A clinical evaluation of the ocular surface, interferometry, and histological assessments of the cornea and conjunctiva were performed. Following the removal of the lacrimal glands, TBUT was shortened significantly, with dimple and random breakup patterns prominently observed. Furthermore, the blink rate in this model increased after dacryoadenectomy, suggesting that this model partially captured the phenotypes of human short TBUT-type dry eye and may be useful as an animal model for investigating potential drug candidates.

Misc.

 133
  • 三田村 浩人, 榛村 重人
    日本の眼科, 92(6) 683-684, Jun, 2021  
  • 西田 幸二, 村上 晶, 東 範行, 島崎 潤, 宮田 和典, 山田 昌和, 外園 千恵, 白石 敦, 榛村 重人, 臼井 智彦, 大家 義則, 池田 陽子, 内野 裕一, 大本 美紀, 倉上 弘幸, 重安 千花, 子島 良平, 三田村 浩人, 森 洋斉, 山田 知美, 堀 裕一, 尾島 俊之, 赤井 規晃, 西田 希, 厚生労働科学研究費補助金難治性疾患政策研究事業「角膜難病の標準的診断法および治療法の確立を目指した調査研究」研究班診療ガイドライン作成委員会, 日本眼科学会, 日本角膜学会, 日本小児眼科学会, 日本緑内障学会
    日本眼科学会雑誌, 125(6) 605-629, Jun, 2021  
  • 關口 真理奈[色川], 水野 未稀, 内野 裕一, 榛村 重人, 坪田 一男
    あたらしい眼科, 38(5) 584-587, May, 2021  
    目的:円錐角膜患者に対する全層角膜移植と深層層状角膜移植の術後経過について比較検討する。対象:2008年3月〜2017年1月に行った円錐角膜患者に対する全層角膜移植と深層層状角膜移植のうち、術後2年以上経過を追跡できた20症例(全層角膜移植群11名11眼、深層層状角膜移植群9名10眼)を対象とした。縫合糸は緩み、断裂、感染があった場合にのみ抜糸とした。結果:術後3年までの眼鏡矯正視力(logMAR換算視力)、球面度数、乱視度数、等価球面度数、角膜形状、角膜内皮細胞密度について、両群間に差はなかった。結論:円錐角膜患者に対する全層角膜移植群および深層層状角膜移植群の3年までの術後経過は両群に差はなかった。(著者抄録)
  • 榛村 重人
    日本眼科学会雑誌, 125(臨増) 151-151, Mar, 2021  
  • 榛村 真智子, 榛村 重人
    眼科手術, 34(1) 5-9, Jan, 2021  
    角膜上皮の幹細胞は角膜輪部の基底細胞層に存在し、オキュラーサーフェスの恒常性維持に関与している。外傷や瘢痕性角結膜症などによって角膜輪部が傷害されると、慢性的な角膜上皮障害や角膜上への結膜組織の侵入を認めるようになる。これを輪部機能不全とよぶ。輪部機能不全に対して内科的治療で対応できなくなったときに、外科的治療の適応となる。治療の選択肢は多数あるが、輪部移植は傷害されている部位を置換するという意味で、もっとも基本となる術式である。輪部移植には大きく分けて他家(アロ)移植と自己移植がある。本稿では他家輪部移植について解説する。(著者抄録)

Teaching Experience

 8

Research Projects

 28

Social Activities

 8